Sotera Health Company (SHC) reported $254.52 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 2.6%. EPS of $0.14 for the same period compares to $0.13 a year ago.
The reported revenue represents a surprise of +3.63% over the Zacks Consensus Estimate of $245.61 million. With the consensus EPS estimate being $0.12, the EPS surprise was +16.67%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sotera Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenues- Sterigenics: $169.68 million compared to the $169.72 million average estimate based on two analysts. The reported number represents a change of +1.9% year over year.
- Net Revenues- Nelson Labs: $52.28 million versus the two-analyst average estimate of $51.17 million. The reported number represents a year-over-year change of -9.4%.
- Net Revenues- Nordion: $32.56 million versus the two-analyst average estimate of $22.93 million. The reported number represents a year-over-year change of +35.6%.
- Segment Income- Sterigenics: $88 million versus the two-analyst average estimate of $87.92 million.
- Segment Income- Nelson Labs: $16.41 million versus the two-analyst average estimate of $14.20 million.
- Segment Income- Nordion: $17.42 million compared to the $10.41 million average estimate based on two analysts.
View all Key Company Metrics for Sotera Health here>>>
Shares of Sotera Health have remained unchanged over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sotera Health Company (SHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
